GeneDx Holdings (WGS) Price to Sales (2020 - 2026)

GeneDx Holdings (WGS) has reported Price to Sales for 7 consecutive years, with 17.88 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Price to Sales fell 30.72% year-over-year to 17.88 in Q2 2026; TTM through Jun 2026 was 4.5, a 38.44% decrease from a year earlier, with the FY2025 full-year figure at 8.9, up 26.2% from the prior year.
• Price to Sales was 17.88 for Q2 2026 at GeneDx Holdings, down from 18.63 in the prior quarter.
• Over five years, Price to Sales peaked at 460.44 in Q1 2022 and troughed at 1.24 in Q4 2023.
• A 5-year average of 43.44 and a median of 18.26 in 2026 frame the typical range for Price to Sales.
• Across the five-year window, Price to Sales sank 98.78% in 2023 and jumped 1709.55% in 2024, its largest moves.
• Over 5 years, Price to Sales stood at 9.43 in 2022, then sank by 86.8% to 1.24 in 2023, then jumped by 1709.55% to 22.52 in 2024, then jumped by 39.63% to 31.44 in 2025, then slumped by 43.13% to 17.88 in 2026.
• The last three Price to Sales figures came in at 17.88 (Q2 2026), 18.63 (Q1 2026), and 31.44 (Q4 2025), per Business Quant data.